Routes of
administration Oral CAS Number 4267-80-5 ChemSpider 48063843 Route Oral administration | ATC code None PubChem CID 71752521 Molar mass 320.5325 g/mol | |
 | ||
Synonyms Methylepithiostanol; Methepitiostane; 2α,3α-Epithio-3-deketo-17α-methyl-4,5α-dihydrotestosterone | ||
Methylepitiostanol (online product names Epistane, Hemapolin, Havoc, Epi Plex), also known as 17α-methylepitiostanol or 2α,3α-epithio-17α-methyl-5α-androstan-17β-ol, is a synthetic androgenic-anabolic steroid (AAS) that was first described in the literature in 1974 but was never marketed. It is the 17α-methylated derivative of epitiostanol, an AAS and antiestrogen formerly used in the treatment of breast cancer in Japan, and similarly to mepitiostane (epitiostanol 17-methyloxycyclopentyl ether), is an orally active version of epitiostanol. Due to its 17α-methyl group, methylepitiostanol is considered to have a high potential for hepatotoxicity. The drug surfaced on the internet as a novel designer steroid in dietary supplements around 2009. It was identified in 2015 in over 30 products sold online that listed it as an ingredient on their product label. As of 2015, the drug is reportedly not a controlled substance. However, methylepitiostanol may degrade in some product containers into desoxymethyltestosterone, which, in contrast, is a controlled substance. Methylepitiostanol is reported to be a prodrug of desoxymethyltestosterone.